Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris
Pemphigus Vulgaris
About this trial
This is an interventional treatment trial for Pemphigus Vulgaris focused on measuring Pemphigus Vulgaris, Chronic Pemphigus, Etanercept, Enbrel, anti-TNF-alpha, TNF-alpha antagonist, biologic, immunomodulator, subcutaneous medication
Eligibility Criteria
Summary Inclusion Criteria: Understand and sign the written informed consent form and be willing and able to comply with the procedures of the study Have a clinical diagnosis of pemphigus vulgaris Have at least 6 active pemphigus lesions (blisters or erosions) Have no adverse effects due to combining etanercept with concurrent pemphigus medications Be on stable dose of current pemphigus medications for at least one month Females of child-bearing potential must have a negative urine pregnancy test prior to treatment and agree to practice an acceptable method of birth control (oral contraceptives, hormonal implant devices, Depo-Provera, condom with spermicide, diaphragm with contraceptive cream or foam, or intrauterine device) during the course of the study Be at least 18 years old at time of enrollment Be able to adhere to the study visit schedule and other protocol requirements
Sites / Locations
- Clinical Unit for Research Trials in Skin